Exicure Inc. (XCUR) Prices 10M Share Common Offering at $2.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
Exicure Announces Pricing of $27.5 Million Public Offering of Common Stock
December 19, 2019 9:20 AM ESTCHICAGO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA) constructs, today announced the pricing of the previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $2.75 per share. Exicure has also granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock to cover overallotments, if any, at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about December 23, 2019... More



